Pharmaceutical company Ipca Laboratories today said its consolidated net profit surged twofold to Rs 205.36 crore for the year ended March 2010.
The company had a consolidated net profit of Rs 100.80 in the previous fiscal.
Total income of the company rose to Rs 1,566.58 crore, compared to Rs 1,292.64 crore in the previous fiscal, Ipca Lab said in a statement.
The company has recommended a final dividend of 50 per cent, or Re 1 per share, for the financial year 2009-10.
The drug firm's revenues from Indian formulations business saw a growth of 25 per cent to Rs 597.84 crore in the FY10 against Rs 476.59 crore in the previous fiscal.
Revenues from export business stood at Rs 489.15 crore in FY10 against 437.17 crore in the previous fiscal.
The company's revenues from active pharmaceutical ingredients (API) stood at Rs 141.63 crore, compared to Rs 108.34 crore in the previous fiscal.
Shares of Ipca Laboratories today closed at Rs 263.45 on the BSE, up 2.45 per cent from its previous close.
